• No results found

programmed death-1 receptor

Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer

<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>

... of programmed death receptor-1/programmed death ligand 1 (PD-1/PD-L1) can stimulate surrounding T cells and thus have antitumor effects in the ...PD- 1/PD-L1 ...

17

A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction

A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction

... and there are no T cells in these cultures providing PD-1. While the PD-1:PD-L1 pathway is well established in adaptive immunity during chronic infections and cancer, its role in acute infections is less ...

11

Upregulation of programmed death 1 on T cells and programmed death ligand 1 on monocytes in septic shock patients

Upregulation of programmed death 1 on T cells and programmed death ligand 1 on monocytes in septic shock patients

... Sepsis produces marked alterations in the expression of membrane-associated co-stimulatory/inhibitory molecules. Expression of these accessory molecules appears to contri- bute to the morbidity/mortality seen not only in ...

9

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma

Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma

... Programmed death 1 (PD-1) receptor is expressed by activated T-cells and engaged by ligands PD-L1 and ...a 1-year survival rate of 42 % that declines to 18 % at 3 years [11]—much ...

5

Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives

Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives

... PD‑1: programmed cell death 1; PD‑L1: programmed cell death 1 ligand 1; CTLA4: cytotoxic T‑lymphocyte‑associated antigen‑4; DC: dendritic cell; TME: tumor ...

11

CXCR2–CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma

CXCR2–CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma

... CXC receptor 2; CXCL1: CXC ligand 1; RFS: Recurrence-free survival; OS: Overall survival; PD-L1: Programmed cell death 1 ligand 1; Treg: Regulatory T; MMP9: Matrix ...

10

Original Article PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes

Original Article PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes

... and programmed death ligand 1 (PD-L1) were expressed on T-cell, B-cell, DC and ...one receptor of co-inhibitor, programmed death 1 (PD-1) was mainly expressed on ...

10

PD 1 tempers Tregs in chronic HCV infection

PD 1 tempers Tregs in chronic HCV infection

... inhibitory receptor programmed death1 (PD-1) and inhibition of effector T cells (Teffs) by CD4 + Foxp3 + Tregs are among the many described mechanisms for achieving a balanced immune ...

5

Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Immunotherapy for Merkel cell carcinoma: a turning point in patient care

... get programmed cell death protein 1 (PD-1), another im- mune checkpoint receptor, or one of its associated ligands (PD-L1), and are now FDA-approved for a variety of can- cers ...

6

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

... anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibody has a good effect in the treatment of non-small cell lung cancer (NSCLC), but not all ...

6

Immunotherapies: The Blockade of Inhibitory Signals

Immunotherapies: The Blockade of Inhibitory Signals

... PD-1: programmed death-1; PD-L1: pro- grammed death-ligand1; BTLA: B and T cell attenua- tor; TCR: T cell receptor; CD: cluster of differentiation; APCs: antigen presenting ...

11

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

... Abstract: T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte- associated antigen (CTLA)-4 and ...

9

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor

... The peptide scaffold library is composed of helix and strand fragments. The reason that we use helices and strands which can form sheets with other strands to construct the designed peptides is that they are stable in ...

10

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

... PD-1: Programmed cell death receptor-1; PD-L1: Programmed cell death ligand-1; NSCLC: Non- small-cell lung cancer; ADC: Adenocarcinoma; SCC: Squamous cell carci- ...

15

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

... cytotoxic T lymphocytes through inhibitory pathways, which are usually initiated by ligand-receptor interactions [19] . PD-1 is one immune checkpoint expressed on the surface of T-cells upon activation ...

11

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

... T-cell receptor sequencing (TCRseq) ...file 1: Table S1Table ...file 1: Table S1Table S6); one of these clones was detected in the original primary tumor ...file 1: Table S1Table S6) per- ...

8

Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study

<p>Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study</p>

... We isolated DNA from 5×10 6 PBMCs with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer ’ s instructions. The concen- tration and purity of the isolated DNA were veri fi ed with the ...

14

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

... cell receptor deep sequencing provides the full spectrum of the B and T cell receptor repertoire and can be used to potentially identify immunosequencing biomarkers in both peripheral blood and tumor ...

25

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer

Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer

... Methods: A total of 383 patients with GC from the Cancer Genome Atlas (TCGA) cohort, 300 patients with GC from the GSE62254 cohort in Gene Expression Omnibus (GEO) were included in the study. A stromal score was ...

13

A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients

A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients

... In recent years, immune inhibitory signaling path- ways have been recognized to play a pivotal role in the maintenance of an immunosuppressive microen- vironment that favors cancer development [13]. One important ...

11

Show all 10000 documents...

Related subjects